Ken Griffin Imago Bio Sciences, Inc. Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$15.03 - $35.96 $35.6 Million - $85.1 Million
-2,367,410 Reduced 96.05%
97,340 $3.5 Million
Q3 2022

Nov 14, 2022
SELL
$14.15 - $19.5 $739,917 - $1.02 Million
-52,291 Reduced 2.08%
2,464,750 $37.1 Million

Others Institutions Holding IMGO

# of Institutions
2
Shares Held
19.3K
Call Options Held
0
Put Options Held
0
View Full List

About Imago BioSciences, Inc.

IMGO Quotes by TradingView
  • Ticker IMGO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,741,600
  • Description
  • Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment o...
More about IMGO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email